Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsRocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del PozoSee the full list of authors
25 March 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanomaGalabina Bozhanova, Jehanne Hassan, Lizzie Appleton, Victoria Jennings, Shane Foo, Martin McLaughlin, Charleen ML Chan Wah Hak, Emmanuel C Patin, Eva Crespo-Rodriguez, Gabby Baker, Edward Armstrong, Matthew Chiu, Hardev Pandha, Adel Samson, Victoria RoulstoneSee the full list of authors
25 March 2022
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancerJacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi, Joseph Colasanti, D Grant McFadden, James J Petrik, Byram W Bridle, Sarah K Wootton
16 March 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axisTianyu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Tingbo Liang
14 March 2022
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8 T cell-dependent antitumor immunity and abscopal effect after local irradiationYi Na Yoon, Eunju Lee, Young-Ju Kwon, Jeong-An Gim, Tae-Jin Kim, Jae-Sung Kim
14 March 2022
Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancerDaniel Alonso-Miguel, Guillermo Valdivia, Diego Guerrera, Maria Dolores Perez-Alenza, Stanislav Pantelyushin, Angela Alonso-Diez, Veronique Beiss, Steven Fiering, Nicole F Steinmetz, Maria Suarez-Redondo, Johannes vom Berg, Laura Peña, Hugo Arias-Pulido
11 March 2022
Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunityJin-Yan Wang, Hengyu Chen, Shu-Zhen Dai, Feng-Ying Huang, Ying-Ying Lin, Cai-Chun Wang, Lei Li, Wu-Ping Zheng, Guang-Hong Tan
7 March 2022
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regressionAdam Nelson, Simon Gebremeskel, Brian D Lichty, Brent Johnston
4 March 2022
Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacyJianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie LiangSee the full list of authors
2 March 2022
Oncolytic adenovirus decreases the proportion of TIM-3 subset of tumor-infiltrating CD8 T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, Kristian Taipale, Otto Hemminki, Minna Oksanen, Matti Kankainen, Juuso Juhila, Anna Kanerva, Timo Joensuu, Siri Tähtinen, Akseli Hemminki
22 February 2022
